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ABSTRACT
Topical and systemic glucocorticoids have long been
considered the most effective therapy for chronic
asthma. Asthma patients who do not respond to sys-
temic administration of high-dose glucocorticoids are
termed ‘steroid-resistant asthmatics’. Recent progress
in the mechanisms of glucocorticoid action goes a
long way to the understanding of steroid resistance.
Several cellular responses to glucocorticoids have
been characterized in steroid-resistant asthma. Based
on molecular biological studies, excessive expression
of glucocorticoid receptor b and c-fos, an inducible
transcription factor, was suggested to result in steroid
resistance. A thorough understanding of the patho-
physiology of steroid-resistant asthma would facilitate
the development of more powerful agents for the treat-
ment of severe asthma.
Key words: bronchial asthma, cytokine, glucocorti-
coid, T cell.
INTRODUCTION
The role of persistent eosinophilic inflammation in the
pathogenesis of bronchial asthma has been well docu-
mented.1 For the management of chronic asthma, the use
of anti-inflammatory agents, including inhaled gluco-
corticoids (GC), is advocated as the first-line treatment in
various asthma guidelines.2 However, it is well-known
that asthmatic patients vary in their responsiveness to
GC therapy.3 ‘Steroid-resistant’ (SR) asthma represents a
group of patients who respond to GC less effectively in
comparison with others. Recent investigations have been
directed towards the cellular and molecular alterations
associated with SR asthma.4–6 Elucidation of the precise
mechanisms involved in steroid resistance may clarify
what mode of GC action(s) is really relevant in the
control of asthma.
STEROID-SENSITIVE VS -RESISTANT ASTHMA
A group of asthmatic patients who had a poor clinical
response to high-dose systemic GC therapy was first
reported by Schwartz et al.7 Later, Corrigan et al. and
Alvarez et al. reported that the difference in patient 
responsiveness to GC could not be explained by 
pharmacokinetic characteristics, including oral absorp-
tion or clearance, of the agents.8,9 To date, there is no
established definition of steroid resistance, although most
recent investigations have defined SR asthma as asthma 
in those patients who demonstrated a less than 15%
improvement in forced expiratory volume in 1 s (FEV1.0)
after a course of oral prednisolone of 20–40 mg daily or
equivalent doses for 10–14 days. Those patients who
demonstrated more than 30% improvement tended to 
be classified as steroid-sensitive (SS) asthma patients.
Kamada et al. studied the effect of oral GC on asthmatic
children whose morning prebronchodilator FEV1.0 was less
than 70% predicted. They reported that more than 60% of
patients who eventually responded to therapy demon-
strated a more than 15% increase in their FEV1.0 within
2–3 days and 93% showed a significant improvement
within 10 days.10 Prolongation of the course of therapy
beyond 10 days did not bring about a significantly greater
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improvement. Based on this finding, 2 weeks of high-dose
prednisolone therapy has been considered appropriate 
to diagnose SR asthma.
IS STEROID RESISTANCE A SYSTEMIC OR LOCAL
PHENOMENON?
Familial GC resistance has been described.11–13 Genomic
mutation in the glucocorticoid receptor (GR) gene has
been reported in several cases. These patients are charac-
terized by extremely high serum cortisol concentrations and
the absence of excessive GC action. They exhibited either
reduced GR numbers, decreased binding affinity for GC 
or poor DNA binding of their GR to the glucocorticoid-
responsive elements (GRE). However, in SR asthma, no
such genomic alterations have been identified.
It is assumed that the effects of GC on the airway, 
but not its systemic effects, are impaired in SR asthma
patients, thereby resulting in equivalent side effects com-
pared with SS asthma patients.14 It has been suggested
that steroid resistance stems from a functional alteration
induced locally by ongoing inflammation via yet
unknown mechanisms. In contrast, SR asthma patients
exhibited significantly less vasoconstrictor response to
GC compared with SS asthma patients, suggesting that
steroid resistance of SR asthmatics reflects a systemic
phenotype.15 So, steroid resistance cannot be explained
by a single theory at present. Multiple pathogeneses may
be involved.
IS SR ASTHMA MORE SEVERE THAN SS 
ASTHMA?
One could imagine that SR asthma may represent
patients suffering from severe asthma. Based on the
severity classification of current asthma guidelines,
steroid-dependent asthmatics requiring continuous sys-
temic steroid therapy represent the most severe patients
(step IV). This raises the question of whether or not SR
asthma defined by the aforementioned criteria is identical
to steroid-dependent asthma. The severity of the patients
and the proportion of those on systemic (oral) steroids
used in recent publications on SR asthma is shown in
Table 1. Many studies on SR asthma apparently recruited
patients with mild asthma. Based on this finding, it is
assumed that steroid resistance per se does not mean
that the patient has severe asthma. However, in several
studies, the SR asthma group did contain more severe
and steroid-dependent patients, suggesting that steroid
resistance may be related to steroid dependence to
some extent.
The clinical and pathophysiologic relationship
between steroid-dependent (severe) asthma and SR
asthma must be clarified to a greater extent. The criteria
used for defining steroid resistance seem unequivocal,
whereas the diagnosis for so-called steroid-dependent
asthma has been hampered by many factors, including
several differential diagnoses, confounding pulmonary
and non-pulmonary disorders, patient compliance etc.16
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Table 1 Is steroid-resistant asthma more severe than steroid-sensitive asthma?
Reference Severity or patient characteristics SR more severe No. patients*
than SS? SR SS
8 Moderate to severe No 13 (3) 24 (4)
%FEV1.0: 49 vs 47
37 Mild No 7 (0) 6 (0)
%FEV1.0: 71 vs 76
38 Mild (No BDI) No 12 (0) 12 (0)
%FEV1.0: 61 vs 64
29 No oral steroids No 6 (0) 6 (0)
%FEV1.0: 56 vs 47
30 Young atopics Yes 17 (12) 12 (0)
%FEV1.0: 57 vs 47
43 Severe (high-dose BDI) No 11 (2) 8 (2)
15 Severe and mild Yes 15 (8) 31 (4)
%FEV1.0: 54 vs 82
*The number shown in the parenthesis is the number of patients who were taking oral steroids.
%FEV1.0, forced expiratory volume in 1 s; BDI, beclomethasone dipropionate.
MECHANISM OF GC ACTION
The understanding of GC action seems mandatory to clarify
the pathogenesis of steroid resistance (Fig. 1). Because GC
are highly lipid soluble, they can easily diffuse across the
plasma membrane and enter the cytoplasm.17 The existence
of specific receptors on the cell surface is still controversial.18
Two splice variants, GR-a and GR-b , have been identified in
the cytoplasm, although only GR-a has the potential of
ligand binding and transcriptional activation.19 Without 
its ligands, GR-a forms an inactive complex with two mole-
cules of heat shock protein (hsp) 90 and other associated
molecules. When GR-a encounters GC, hsp are dissoci-
ated from GR and then the GC–GR complex is formed. The
GC–GR complex translocates into the nucleus and binds 
as a homodimer to GRE located in the regulatory regions 
of the target genes to cause up- or downregulation of tran-
scription. It has been reported that the GC–GR complex
also interacts with other transcription factors, such as activa-
tor protein (AP)-1 and nuclear factor (NF)- k B,20–23 thereby
interfering with the transcriptional activation of several
genes through these elements. So, multiple processes may
become the candidates responsible for GC resistance.
CELLULAR AND MOLECULAR INVESTIGATIONS
OF SR ASTHMA
Current diagnosis of SR asthma is based solely on the
therapeutic effects of in vivo administration of GC. Great
efforts have been made to characterize SR asthma by 
biological responses. One of the earliest studies reported
a defect in the suppression of complement receptor
expression on monocytes following GC therapy.24 The
proliferation of peripheral blood T cells in response to
Phaseolus vulgaris agglutinin (PHA) and the production of
monocyte-derived neutrophil chemotactic factors by
peripheral blood mononuclar cells (PBMC) of SR asth-
matics have also been reported to be less sensitive to
GC.25–27 Tumor necrosis factor (TNF) production by
lipopolysaccharide-stimulated PBMC was also less sensi-
tive to steroid action.28
Based on the fact that T lymphocytes are essentially
involved in asthma, recent investigations have focused
on possible T cell dysfunction in SR asthma. Corrigan 
et al. have reported that peripheral blood T cells of SR
asthma expressed increased amounts of activation
markers, such as CD25 and human leukocyte antigen
(HLA)-DR, and not only PHA-induced proliferation but
also interleukin (IL)-2 and interferon (IFN)- g production
was less sensitive to GC action.8 These findings were
confirmed by an in vivo study.29 After a 1 week course of
40 mg daily prednisone therapy, the number of IL-4 and
IL-5 mRNA-positive cells recovered in the bronchoalve-
olar lavage fluid was decreased in SS asthma but not in
SR asthma. The number of IFN- g mRNA-positive cells
was increased in SS asthma but decreased in SR
asthma. Taken together, these findings strongly suggest
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Fig. 1 Molecular understandings of
glucocorticoid (GC) action. Gluco-
corticoid resistance may result from
multiple steps. 1. Decreased cytoplas-
mic concentration of GC due to the
accelerated clearance etc. 2. A lower
number of glucocorticoid receptors
(GR). 3. A lower affinity between the
GC and GR. 4. Impaired dissociation
of heat shock protein (hsp) 90. 
5. Destabilization of GR molecules 
by dephosphorylation. 6. Impaired
translocation of the GC–GR complex.
7. A lower affinity between GC–GR 
and glucocorticoid-responsive ele-
ments (GRE). 8. An increase in the
molecular interaction between GR
and activator protein (AP)-1 or GR
and nuclear factor (NF)-k B etc. 9. An
increased expression of GR-b . 10. An
increased expression of activating
transcription factors. TCR, T cell recep-
tor; NF-AT, nuclear factor for activated
T cells.
that T cells of SR asthma have a different responsiveness
to GC action both in vitro and in vivo.
ALTERATION IN GC–GR AFFINITY, ITS
REVERSIBILITY AND GR-b
Sher et al. performed a [3H]-dexamethasone radioligand
binding assay using PBMC obtained from 17 SR asthma
patients.30 They described type I SR asthma (15/17), in
which GC–GR binding affinity was decreased three- to
four-fold compared with SS asthma, whereas the total
GC binding sites were increased three- to four-fold. Type
II SR asthma (2/17) was characterized by the reduced
number of total GC binding sites with apparently normal
GC–GR binding affinity. The type I SR abnormality was
reversed when cells were cultured in vitro for 48 h. Later,
Kam et al. reported that the in vitro incubation of normal
(SS) PBMC with IL-2 and IL-4 for 48 h reduced the
GC–GR binding affinity in the T cell population (e.g.
induction of type II SR abnormality).31 In contrast, Spahn
et al. demonstrated that IL-13 reduced GC–GR binding
affinity in monocytes but not in T cells.32 These findings
suggest that the alteration in the type I SR asthma was 
a reversible phenomenon, possibly induced by the 
exposure of T cells and/or monocytes to inflammatory
cytokines in vivo. Leung et al. have reported that the
number of GR-b -positive cells was increased in PBMC of
SR asthma patients.33 Culturing cells in the presence of
both IL-2 and IL-4 increased the number of GR-b -positive
cells, consistent with the report of Kam et al.31 The GR-a
and GR-b are splice variants of a single GR gene and
have N-terminal amino acids in common. The GR-b is
only different from GR-a in its C-terminal 15 amino acids
instead of the 50 amino acids present in GR-a . Because
GR-b acts as a dominant negative form of GR-a ,19,34,35 the
increase in GR-b content may explain the apparent
reduction in GC–GR binding affinity.
ALTERATION IN GR–GRE AFFINITY AND
AP-1 INDUCTION
Adcock et al. reported that the amounts of GC–GR 
complexes that bind GRE were significantly less in the
PBMC of SR asthmatics compared with those of SS asth-
matics, whereas the affinity between the GC–GR
complex and GRE was equivalent.36 They also reported
that the binding activity to the AP-1 element in the PBMC
of SR asthmatics was twice as high as that of SS asthmat-
ics, which could not be suppressed by dexamethasone
treatment.37 More recently, they found that c-fos expres-
sion of phorbol myristate acetate (PMA)-induced PBMC
of SR asthmatics was four-fold higher than that of SS
asthmatics.38 These results collectively suggest that upreg-
ulation of c-fos, one member of the AP-1 family, may 
result in the lower responsiveness to GC in SR asthma. 
The functional relationship between the level of c-fos and
the GC responsiveness warrants further investigation.
OTHER MECHANISMS POTENTIALLY INVOLVED IN
GC RESISTANCE
Cyclic AMP-responsive element binding protein (CREB)-
binding protein (CBP) and steroid receptor coactivator-1
(SRC-1) are the transcriptional coactivators that associate
with GR.39,40 They also associate with the transcription fac-
tor NF-k B. The competition for the transcriptional coacti-
vators between the GR and NF- k B may be another
mechanism for steroid resistance, because NF-k B is
induced by inflammatory cytokines such as IL-1 and TNF-a .
FUTURE DIRECTIONS
At this moment, immunosuppressants, including cyclo-
sporine and FK506, seem promising for the treatment of
SR asthma.25,41,42 Increasing the dose of steroids by
applying agents with fewer side effects (soft steroids) may
be another practical approach. Upregulation of c-fos
and GR-b seem good candidates responsible for the
development of steroid resistance, but do not exclude
other mechanisms. The number of molecules involved in
the signal transduction, gene transcription and prolifera-
tion of inflammatory cells is growing rapidly. Elucidation
of such molecules that lead to steroid-dependent asthma
may help greatly the development of novel therapeutic
agents in the near future.
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